Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 60

1.

High-throughput ectopic expression screen for tamoxifen resistance identifies an atypical kinase that blocks autophagy.

Gonzalez-Malerva L, Park J, Zou L, Hu Y, Moradpour Z, Pearlberg J, Sawyer J, Stevens H, Harlow E, LaBaer J.

Proc Natl Acad Sci U S A. 2011 Feb 1;108(5):2058-63. doi: 10.1073/pnas.1018157108. Epub 2011 Jan 13.

2.

LAMP3 is involved in tamoxifen resistance in breast cancer cells through the modulation of autophagy.

Nagelkerke A, Sieuwerts AM, Bussink J, Sweep FC, Look MP, Foekens JA, Martens JW, Span PN.

Endocr Relat Cancer. 2014 Jan 16;21(1):101-12. doi: 10.1530/ERC-13-0183. Print 2014 Feb.

3.

Macroautophagy inhibition sensitizes tamoxifen-resistant breast cancer cells and enhances mitochondrial depolarization.

Qadir MA, Kwok B, Dragowska WH, To KH, Le D, Bally MB, Gorski SM.

Breast Cancer Res Treat. 2008 Dec;112(3):389-403. doi: 10.1007/s10549-007-9873-4. Epub 2008 Jan 3.

PMID:
18172760
4.

Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients.

Holm C, Rayala S, Jirström K, Stål O, Kumar R, Landberg G.

J Natl Cancer Inst. 2006 May 17;98(10):671-80.

PMID:
16705121
5.

Tamoxifen enhances the cytotoxic effects of nelfinavir in breast cancer cells.

Brüning A, Friese K, Burges A, Mylonas I.

Breast Cancer Res. 2010;12(4):R45. doi: 10.1186/bcr2602. Epub 2010 Jul 1.

6.

Characterization of BCAR4, a novel oncogene causing endocrine resistance in human breast cancer cells.

Godinho M, Meijer D, Setyono-Han B, Dorssers LC, van Agthoven T.

J Cell Physiol. 2011 Jul;226(7):1741-9. doi: 10.1002/jcp.22503.

PMID:
21506106
7.

CtIP silencing as a novel mechanism of tamoxifen resistance in breast cancer.

Wu M, Soler DR, Abba MC, Nunez MI, Baer R, Hatzis C, Llombart-Cussac A, Llombart-Bosch A, Aldaz CM.

Mol Cancer Res. 2007 Dec;5(12):1285-95. doi: 10.1158/1541-7786.MCR-07-0126.

9.

MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.

Brünner N, Boysen B, Jirus S, Skaar TC, Holst-Hansen C, Lippman J, Frandsen T, Spang-Thomsen M, Fuqua SA, Clarke R.

Cancer Res. 1997 Aug 15;57(16):3486-93.

10.

Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.

deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, Roth RA, Hidalgo M.

Clin Cancer Res. 2004 Dec 1;10(23):8059-67.

11.

Elevated Src kinase activity attenuates Tamoxifen response in vitro and is associated with poor prognosis clinically.

Morgan L, Gee J, Pumford S, Farrow L, Finlay P, Robertson J, Ellis I, Kawakatsu H, Nicholson R, Hiscox S.

Cancer Biol Ther. 2009 Aug;8(16):1550-8.

PMID:
19830888
12.

An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells.

Aesoy R, Sanchez BC, Norum JH, Lewensohn R, Viktorsson K, Linderholm B.

Mol Cancer Res. 2008 Oct;6(10):1630-8. doi: 10.1158/1541-7786.MCR-07-2172.

13.

Genetic screen identifies insulin-like growth factor binding protein 5 as a modulator of tamoxifen resistance in breast cancer.

Ahn BY, Elwi AN, Lee B, Trinh DL, Klimowicz AC, Yau A, Chan JA, Magliocco A, Kim SW.

Cancer Res. 2010 Apr 15;70(8):3013-9. doi: 10.1158/0008-5472.CAN-09-3108. Epub 2010 Mar 30.

14.

Statistical analysis of array expression data as applied to the problem of tamoxifen resistance.

Hilsenbeck SG, Friedrichs WE, Schiff R, O'Connell P, Hansen RK, Osborne CK, Fuqua SA.

J Natl Cancer Inst. 1999 Mar 3;91(5):453-9.

PMID:
10070945
15.

[Involvement of epidermal growth factor receptor signaling pathway in tamoxifen resistance of MCF-7 cells].

Zhen LL, Zhu X, Zheng W, Wang XY, Wu ZY.

Ai Zheng. 2006 Jul;25(7):839-43. Chinese.

PMID:
16831274
16.

Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant.

Fan M, Yan PS, Hartman-Frey C, Chen L, Paik H, Oyer SL, Salisbury JD, Cheng AS, Li L, Abbosh PH, Huang TH, Nephew KP.

Cancer Res. 2006 Dec 15;66(24):11954-66.

17.

Role of PKC-ERK signaling in tamoxifen-induced apoptosis and tamoxifen resistance in human breast cancer cells.

Li Z, Wang N, Fang J, Huang J, Tian F, Li C, Xie F.

Oncol Rep. 2012 Jun;27(6):1879-86. doi: 10.3892/or.2012.1728. Epub 2012 Mar 15.

PMID:
22427054
18.

Carcinoembryonic antigen cell adhesion molecule 6 predicts breast cancer recurrence following adjuvant tamoxifen.

Maraqa L, Cummings M, Peter MB, Shaaban AM, Horgan K, Hanby AM, Speirs V.

Clin Cancer Res. 2008 Jan 15;14(2):405-11. doi: 10.1158/1078-0432.CCR-07-1363. Erratum in: Clin Cancer Res. 2008 Jul 1;14(13):4355-6.

19.

Curcumin induces cell death and restores tamoxifen sensitivity in the antiestrogen-resistant breast cancer cell lines MCF-7/LCC2 and MCF-7/LCC9.

Jiang M, Huang O, Zhang X, Xie Z, Shen A, Liu H, Geng M, Shen K.

Molecules. 2013 Jan 8;18(1):701-20. doi: 10.3390/molecules18010701.

20.

A candidate molecular signature associated with tamoxifen failure in primary breast cancer.

Vendrell JA, Robertson KE, Ravel P, Bray SE, Bajard A, Purdie CA, Nguyen C, Hadad SM, Bieche I, Chabaud S, Bachelot T, Thompson AM, Cohen PA.

Breast Cancer Res. 2008;10(5):R88. doi: 10.1186/bcr2158. Epub 2008 Oct 17.

Supplemental Content

Support Center